Clinical Trials

Noxopharm announces first Covid-19 patient treated in Veyonda study

As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company’s Phase 1 NOXCOVID-1 study.

Pfizer, Sangamo dose first participant in phase 3 study of Hemophilia A gene therapy treatment

Pfizer and Sangamo Therapeutics, a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients.

GSK, Vir Biotechnology to expand Covid-19 treatment study

GlaxoSmithKline (GSK) and Vir Biotechnology have announced that they will expand the study of a VIR-7831 (GSK4182136) monoclonal antibody to treat Covid-19.

Eureka initiates trial to evaluate ET140203 ARTEMIS T Cell Therapy in HCC

Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the Company has initiated a Phase I/II clinical trial of its ET140203 ARTEMIS T cell therapy in adult patients with hepatocellular carcinoma (HCC), the predominant type of liver cancer. The Phase I portion of the ARYA-1 study is now open for enrollment.

Alnylam reports positive results from ILLUMINATE-B phase 3 study of Lumasiran

Alnylam Pharmaceuticals announced positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1).

Kuur Therapeutics announces first patients dosed with allogeneic CAR-NKT cell therapy

Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of hematological and solid malignancies, today announced the treatment of the first patients in its ANCHOR phase 1 study of KUR-502, an allogeneic CAR-NKT therapy.

MedinCell begins first Covid-19 clinical study with Ivermectin

French clinical-stage pharmaceutical firm MedinCell has commenced the first clinical trial of its Covid-19 prevention programme.

ViiV begins implementation science study for HIV treatment regimen candidate in Europe

ViiV Healthcare announced the start of the CARISEL study (Cabotegravir And Rilpivirine Implementation Study in European Locations), which aims to evaluate the best approaches to implementing an investigational, every-two-month, injectable HIV treatment regimen into clinical practice in Europe.

Inovio announces partial hold on Covid-19 vaccine candidate trial over FDA queries

Inovio has announced the partial hold on its planned phase 2/3 trial of its Covid-19 vaccine candidate INO-4800 due to additional queries from the US Food and Drug Administration (FDA).